Cardiovascular disease. Cardiovascular disease, unspecified
Conditions
Interventions
Intervention 1: Intervention group: The recipient of empagliflozin 25 mg tablets manufactured by Farmashi Pharmaceutical Company, Iran, one day and one to two hours before coronary intervention. Inter
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Age 18-80 years Ischemic heart diseases patients candidate for angioplasty and stentstent insertion Filling of consent form
Exclusion criteria
Exclusion criteria: History of infarction History of open heart surgery in the last 3 months Renal dysfunction Dialysis Failed History of Coronary Angioplasty cardiogenic shock cancer Liver failure Autoimmune disease Pregnancy History of serious allergy to empagliflozin Inability in filling and understanding of the consent form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CTnI level. Timepoint: 8 hours and 24 hours after the intervention. Method of measurement: ELISA kits.;Hs-CRP level. Timepoint: 24 hours after the intervention. Method of measurement: ELISA kits. | — |
Secondary
| Measure | Time frame |
|---|---|
| Major Adverse Cardiac Effects. Timepoint: 1 month after hospital discharge. Method of measurement: Follow up by phone. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHosein Behzad Vakilabad
Tabriz University of Medical Sciences
Outcome results
None listed